Adverse effects related to paediatric influenza vaccination and its influence on vaccination acceptability: A survey study conducted in The Region of Murcia, Spain

Matilde Zornoza Moreno¹, Jaime Pérez¹, María Gómez Moreno¹, María Valcárcel Gómez¹, Marta Pérez Martínez¹, and Francisca Tornel Miñarro¹

¹Región de Murcia Consejería de Sanidad

June 26, 2024

Abstract

Background: During the 2022-23 season, three autonomous communities recommended influenza vaccination for all children between 6 and 59 months. The objective is to evaluate the adverse effects associated with the administered influenza vaccines in the Region of Murcia, as well as their influence on the recommendation of the same to acquaintances or repetition in future seasons. Material and methods: Cross-sectional descriptive study with an online questionnaire sent to the parents of vaccinated minors of 6-23 months of age receiving inactivated intramuscular vaccine (IIV) or 24-59 months of age receiving live-attenuated intranasal vaccine (LAIV). Results: among 4,971 surveys received the most common adverse effect for LAIV and IIV were runny nose (40.90%) and local pain (31.94%) respectively. Sixty percent of adverse effects lasted [?]1 day, and around 10% lasted [?]3 days. The interference of adverse effects with the minor’s daily life was very infrequent (3.32%), as was the need for visiting the medical office (2.68%). Overall, 96.44% of parents would recommend influenza vaccination to friends and relatives after the experience. Only 3.56% would not recommend it, while 1.68% would not vaccinate their child against influenza again. The most frequently cited reason being adverse effects. Conclusions: Our study shows the safety of influenza vaccines. Despite the low impact of adverse effects, they influence some parents in their intention to continue vaccinating or recommending it to acquaintances, which remarks the need to reinforce the information given to parents so that this fact does not influence.
A.

% of adverse effects

- Runny nose: 40.90%
- Malaise: 21.99%
- Low-grade fever: 18.09%
- Decreased appetite: 25.56%
- Moderate fever: 14.61%
- Muscle pain: 15.48%
- Headache: 15.11%
- High fever: 10.30%
- Nose bleed: 11.04%
- Skin rash: 10.87%

B.

% of adverse effects

- Malaise: 31.04%
- Low-grade fever: 27.46%
- Moderate fever: 15.35%
- Muscle pain: 12.99%
- Headache: 12.29%
- High fever: 8.33%
- Local pain: 31.94%
- Fatigue: 23.82%
- Local reddening: 21.53%
- Local swelling: 19.38%
- Local induration: 12.85%
- Sweating: 11.25%
- Joint pain: 10.28%
- Shivering: 10.00%

LAIV

IIV

Total

% of adverse effects

- Duration ≤ 1 day: 61.46%
- Duration 1 day: 12.17%
- Duration 2 days: 14.63%
- Duration 3 days: 12.33%
- Duration >3 days: 3.15%

LAIV

IIV

Total

% of adverse effects

- Duration ≤ 1 day: 59.27%
- Duration 1 day: 21.45%
- Duration 2 days: 15.42%
- Duration 3 days: 13.83%
- Duration >3 days: 3.81%

LAIV

IIV

Total

% of adverse effects

- Duration ≤ 1 day: 60.96%
- Duration 1 day: 15.42%
- Duration 2 days: 13.83%
- Duration 3 days: 3.81%
- Duration >3 days: 6.25%